Nicholas P. Restifo, M.D.
Dr. Restifo pioneered the use of T cell-based immunotherapies. The Restifo group was amongst the first to identify myeloid-derived cell subsets that impair anti-tumor T cell responses. His work on immunoablation underlies many of the current generation of cellular therapies in the clinic. Dr. Restifo’s group was the first to discover a novel subset of long-lived human T memory stem cells in humans. These fundamental discoveries are aimed at improving the treatment of adults and children with metastatic cancer.
Designing Potent New Cancer Immunotherapies
Our goal is to design new immunotherapies for patients with advanced cancer. Our strategy is based on the use of animal models and human in vitro assays to test hypotheses. We then translate the most promising of these therapies into human clinical trials, which often generate new questions to be tested experimentally. The process is an iterative one that involves close collaboration with basic researchers, biotech scientists and experimental clinicians.
Our work focuses on immunotherapy based on the adoptive transfer of naturally-occurring and gene-engineered tumor-specific T cells. We explore the signals that T cells receive within tumor masses, and what T cells must do to trigger the eradication of tumor cells.
Current efforts are focused on the use of stem cell-like anti-tumor T cells to induce curative responses patients with metastatic cancer who have failed other available forms of therapy. These efforts are aimed at reprogramming the exhausted and senescent T cells that are characteristic of the immune response to growing tumors. We currently treat about 120 patients per year with naturally-occurring or gene-engineered adoptively transferred T cells.
Effectiveness of T cell-based immunotherapies. T cell-based immunotherapy using naturally-occurring and genetically-engineered T cells is demonstrably capable of inducing complete and probably curative responses in some patients with advanced metastatic cancer. Significant evidence indicates that less-differentiated T cells, including those that have longer telomeres and higher levels of CD27, are associated with a greater likelihood of objective response in adoptive T cell therapy (ACT). These findings are corroborated in our tumor-specific T-cell receptor transgenic murine model (Pmel-1) in which there is a progressive loss of anti-tumor function as T-cells mature towards terminal differentiation. The robust clinical response associated with less-differentiated phenotypes of anti-tumor T cells suggests that the efficacy of ACT may be improved with transfer of less-differentiated cells.
In new work from our laboratory (Roychoudhuri R, et al., Nature, in press) as well as unpublished experiments, we have identified several candidate transcription factors that are differentially expressed in naive and stem cell-like T cells and have preliminary evidence that a retroviral transduction of these transcription factors results in successful reprogramming. We are exploring the possibilities that lineage reprogramming of terminally differentiated T cells could significantly improve the effectiveness of ACT in treating patients with metastatic cancer. Alternatively, nuclear reprogramming through iPSC intermediates is capable of achieving the same goal.
Despite years of investigational use, cellular immunotherapy remains an experimental treatment, only available at a very few centers world-wide. Patients with metastatic cancer who have failed available forms of treatment in the community need the option for curative therapy. Studies support the existence of cancer stem cells (CSC) resistant to current forms of therapy. We thus seek to restore multipotency and stemness to anti-tumor T cells. This strategy is akin to fighting fire with fire.
Evidence for the existence of a stem cell-like state in lymphocytes has been developed in our laboratory and elsewhere. Extensive data in mice and in humans supports the concept that younger anti-tumor T cells, such as human T memory stem cells (Tscm) described by our laboratory, are logs more effective than the cells employed in current clinical trials. An increasingly sophisticated understanding of the ontogeny of peripheral T cells has now led to the possibility of inducing plasticity in T cells to modulate pluripotency and expand the pool of multipotent tumor-specific T cells with the aim of enhancing the immune destruction of metastatic cancer.
Current projects in the laboratory include:
- Generation of iPSC from tumor-specific T cells
- Redifferentiation of iPSC into mature naive or Tscm cells
- Safety and efficacy testing of reprogrammed human T cells in humanized mouse models
- Development and conduct of early phase clinical trials using the adoptive transfer of younger, less-differentiated anti-tumor T cells to patients with metastatic cancers.
Selected Recent Publications
- Nature. Nature. 2016 Sep 14. doi: 10.1038/nature19364. : [Epub ahead of print], 2016. [ Journal Article ]
- Cell. Aug 25;166(5): 1117-1131, 2016. [ Journal Article ]
- Nat Immunol. . Jul;17(7): 851-60, 2016. [ Journal Article ]
- Nat Med. . Jan;22(1): 26-36, 2016. [ Journal Article ]
- Cell Metab.. Jan 12;23(1) : 63-76, 2016. [ Journal Article ]
Dr. Nicholas Restifo is a pioneer in the field of cancer immunotherapy. He was recruited from Memorial Sloan Kettering Cancer Center where he was inspired by Lloyd Old and Murray Brennan. Since joining the NCI in 1989, his research has focused entirely on T lymphocytes because they are at the heart of anti-tumor immunity.
He is an honors graduate from The Johns Hopkins University and obtained his MD from New York University. He became a principal investigator in 1993 and has authored or co-authored more than 300 papers and book chapters on cancer immunotherapy. His most recent efforts include a focus on how elements – literally from the periodic table – influence cancer immunity. These include work on how oxygen can inhibit anti-tumor immunity and how potassium ions from dying cancer cells can shut down the anti-tumor response.
Successful treatment of patients with cancer is the goal of his laboratory, and his therapeutic approaches employ adoptive T cell transfer, gene modification and cellular reprogramming. Basic aspects of tumor and T cell immunology inform novel therapeutic interventions in the clinic.
|David Clever||Guest Researcher|
|Arash Eidizadeh||Postbaccalaureate Fellow (CRTA)|
|Robert Eil M.D.||Clinical Fellow|
|Devikala Gurusamy Ph.D.||Postdoctoral Fellow (Visiting)|
|Amanda Henning Ph.D.||Postdoctoral Fellow (CRTA)|
|Rafiqul Islam Ph.D.||Postdoctoral Fellow (Visiting)|
|Jae Ho Kim||Postbaccalaureate Fellow (CRTA)|
|Rigel Kishton Ph.D.||Postdoctoral Fellow (CRTA)|
|Nicholas Klemen M.D.||Clinical Fellow|
|Ping-Hsien Lee Ph.D.||Postdoctoral Fellow (Visiting)|
|Anthony Leonardi||Predoctoral Fellow|
|Takuya Maeda Ph.D.||Postdoctoral Fellow (Visiting)|
|Gautam Mehta M.D.||Clinical Fellow|
|Douglas Palmer||Research Biologist|
|Jenny Pan M.D.||Clinical Fellow|
|Shashankkumar Patel||Predoctoral Fellow|
|Madusudhanan Sukumar Ph.D.||Research Fellow|
|Naritaka Tamaoki Ph.D.||Research Fellow|
|Raul Vizcardo Ph.D.||Research Fellow|
|Suman Vodnala Ph.D.||Postdoctoral Fellow (Visiting)|
|Tori Yamamoto||Predoctoral Fellow|
|Zhiya Yu||Research Biologist|